Analysed PURETECH HEALTH PLC - ADR (PRTC:NASDAQ) News Sources
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
02-04-2026
yahoo.com
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
02-04-2026
yahoo.com
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
25-03-2026
yahoo.com
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
19-02-2026
yahoo.com
PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the company
03-01-2026
yahoo.com
What is the current price of PURETECH HEALTH PLC - ADR (PRTC:NASDAQ)?
The current price of PURETECH HEALTH PLC - ADR (PRTC:NASDAQ) is $18.05.
PURETECH HEALTH PLC - ADR (PRTC:NASDAQ) absolute price change since previous trading day?
The absolute price change of PURETECH HEALTH PLC - ADR (PRTC:NASDAQ) since the previous trading day is $-0.31.
PURETECH HEALTH PLC - ADR (PRTC:NASDAQ) percentage price change since previous trading day?
The percentage price change of PURETECH HEALTH PLC - ADR (PRTC:NASDAQ) since the previous trading day is -1.6885%.
What is the most recent average sentiment score for PURETECH HEALTH PLC - ADR (PRTC:NASDAQ)?
The most recent average sentiment score for PURETECH HEALTH PLC - ADR (PRTC:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for PURETECH HEALTH PLC - ADR (PRTC:NASDAQ)?
The most recent sentiment for PURETECH HEALTH PLC - ADR (PRTC:NASDAQ) is .
SEC-8K** Filing Available For PURETECH HEALTH PLC - ADR (PRTC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.